Chee-Seng Tan, MRCP, David Gilligan, FRCPE, Dr Simon Pacey, FRCP

Slides:

Advertisements

Similar presentations

Interplay between HDAC3 and WDR5 Is Essential for Hypoxia-Induced Epithelial- Mesenchymal Transition Min-Zu Wu, Ya-Ping Tsai, Muh-Hwa Yang, Chi-Hung Huang,

Advertisements

The Microbiome and Cancer: Is the ‘Oncobiome’ Mirage Real? Ryan M. Thomas, Christian Jobin Trends in Cancer Volume 1, Issue 1, Pages (September 2015)

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity Cai-Hong.

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Volume 6, Issue 7, Pages (July 2005)

Steroid-related emphysematous cystitis in an EGFR-mutant patient with lung adenocarcinoma while on gefitinib treatment Diego Marquez-Medina, Sanjay Popat

Volume 64, Pages e1-e3 (January 2017)

Thank God for Richard Dawkins?

Paediatric HIV-1 infection

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

Volume 13, Issue 12, Pages (December 2012)

Volume 371, Issue 9611, Pages (February 2008)

Volume 9, Issue 12, Pages (December 2008)

Volume 9, Issue 5, Pages (May 2008)

SC17.02 Lung Cancer in China: Challenges and Perspectives

Aspirin in the prevention of cancer – Author's reply

Genetics of lung cancer susceptibility and COPD

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa.

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

Theo Nicholaou, Rachel Wong, Ian D Davis The Lancet

OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer

Gene therapy in haematology and oncology

Gene therapy—where are we?

Effective cross-sector collaborations create sustainability

Volume 17, Issue 9, Pages (September 2016)

Incident diabetes in clinical trials of antihypertensive drugs

Overcoming resistance of cancer stem cells

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Psychological response and survival in breast cancer

Volume 13, Issue 12, Pages (December 2012)

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients Jangchul Park, MD, Chiaki Kondo, MD, Junichi.

Amanda Rojek, MBBS, Prof Peter Horby, FRCP, Dr Jake Dunning, MRCP

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Confessions of a journal junkie

Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base Kathryn E. Engelhardt,

Volume 130, Issue 6, (September 2007)

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Telling it like it isn't: truth and lies in a post-9/11 world

Volume 9, Issue 4, Pages (April 2008)

Thank God for Richard Dawkins?

Erratum Journal of Thoracic Oncology

Low-technology approaches

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Thank you to our diverse (but not diverse enough) reviewers

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next- Generation Sequencing and Successfully Treated with a MET Inhibitor Carrie.

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

A remarkable report card on progress in COPD

Volume 21, Issue 9, Pages (September 2014)

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer Judith Elizabeth Carser, MB, BCh, MRCR, Yvonne Jane Summers,

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

Refining treatment choices for ADHD

Cancer: The Transforming Power of Cell Competition

Volume 371, Issue 9611, Pages (February 2008)

Volume 134, Issue 6, (September 2008)

Volume 21, Issue 9, Pages (September 2014)

Ibrutinib Treatment of CLL: The Cancer Fights Back

A Review of First-Line Treatment for Small-cell Lung Cancer

Elevated Preoperative C-reactive Protein Predicts Poor Cancer Specific Survival in Patients Undergoing Resection for Non-small Cell Lung Cancer Caroline.

Sickle cell disease: a new era

Autism, maths, and sex: the special triangle

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

Presentation transcript:

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer Chee-Seng Tan, MRCP, David Gilligan, FRCPE, Dr Simon Pacey, FRCP The Lancet Oncology Volume 16, Issue 9, Pages e447-e459 (September 2015) DOI: 10.1016/S1470-2045(15)00246-6 Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure Timeline in understanding the biology and therapeutic targeting of EGFR-mutant lung cancer EMT=epithelial to mesenchymal transition. SCLC=small-cell lung cancer. MET=mesenchymal to epithelial transition. CTC=circulating tumour cell. ctDNA=circulating tumour DNA. The Lancet Oncology 2015 16, e447-e459DOI: (10.1016/S1470-2045(15)00246-6) Copyright © 2015 Elsevier Ltd Terms and Conditions